Q06124 (PTN11_HUMAN) Homo sapiens (Human)
Tyrosine-protein phosphatase non-receptor type 11 UniProtKBInterProSTRINGInteractive Modelling
593 aa; Sequence (Fasta) ; (Isoform 1; Isoform 3);
5 identical sequences: Pongo abelii: A0A2J8XKS7; Pan troglodytes: K7DQU5, K7B611; Macaca mulatta: H9Z053; Rhinopithecus roxellana: A0A2K6PEZ1
It is possible new templates exist for this target since these models were created.
Available Structures
100 Experimental Structures
| Description | PDB ID | Oligo-state | Range | Ligands | ||
|---|---|---|---|---|---|---|
| SHP2 catalytic domain in complex with IRS1 (625-639) phosphopeptide (pTyr-632, pSer-636) |
Heteromer P35568; | 5×GOL; 1×EOH; | ||||
| Assess | ||||||
| SHP2 catalytic domain in complex with CD28 (183-198) phosphopeptide (pTyr-191, p-Thr-195) |
Heteromer P10747; | 1×GOL; | ||||
| Assess | ||||||
| SHP2 catalytic domain in complex with IRS1 (889-901) phosphopeptide (pSer-892, pTyr-896) |
Heteromer P35568; | 1×GOL; | ||||
| Assess | ||||||
| Crystal Structure of Monobody Mb(SHP2PTP_13)/SHP2 PTP Domain Complex |
Heteromer | 1×FLC; | ||||
| Assess | ||||||
| Crystal structure of SHP2_SH2-CagA EPIYA_C peptide complex |
Heteromer P55980; | |||||
| Assess | ||||||
| Crystal structure of PTPN11 tandem SH2 domains in complex with a TXNIP peptide |
Heteromer Q9H3M7; | 7×UNX; | ||||
| Assess | ||||||
| Crystal structure of SHP2_SH2-CagA EPIYA_D peptide complex |
Heteromer P55980; | |||||
| Assess | ||||||
| Crystal Structure of Monobody CS1/SHP2 C-SH2 Domain Complex |
Heteromer P02751; | |||||
| Assess | ||||||
| C-SH2 domain of SHP-2 in complex with phospho-ITSM of PD-1 |
Heteromer Q15116; | |||||
| Assess | ||||||
| Structure of the N-SH2 domain of the human tyrosine-protein phosphatase non-receptor type 11 in com… |
Heteromer Q15116; | |||||
| Assess | ||||||
| Structure of the N-SH2 domain of the human tyrosine-protein phosphatase non-receptor type 11 in com… |
Heteromer Q15116; | |||||
| Assess | ||||||
| Crystal Structure of Monobody NSa1/SHP2 N-SH2 Domain Complex |
Heteromer P02751; | |||||
| Assess | ||||||
| SHP2 SH2 domain in complex with GAB1 peptide |
Heteromer Q13480; | |||||
| Assess | ||||||
| Crystal structure of the synthetic protein in complex with pY peptide |
Heteromer | 1×MG; | ||||
| Assess | ||||||
| Crystal structure of the tyrosine phosphatase SHP-2 with Y279C mutation | monomer | 5×EDO; 1×GOL; 2×PEG; 1×PGE; | ||||
| Assess | ||||||
| Crystal structure of the tyrosine phosphatase SHP-2 with Q506P mutation | monomer | 6×EDO; 2×GOL; | ||||
| Assess | ||||||
| The atomic structure of SHP2 E76A mutant in complex with allosteric inhibitor 9b | monomer | 1×8J6; | ||||
| Assess | ||||||
| Crystal structure of the tyrosine phosphatase SHP-2 with E139D mutation | monomer | 7×EDO; 1×PEG; | ||||
| Assess | ||||||
| Crystal structure of the tyrosine phosphatase SHP-2 with N308D mutation | monomer | 4×EDO; 1×GOL; | ||||
| Assess | ||||||
| Crystal structure of the tyrosine phosphatase SHP-2 with D61G mutation | monomer | 5×EDO; | ||||
| Assess | ||||||
| Closed structure of active SHP2 mutant E76D bound to SHP099 inhibitor | monomer | 1×5OD; | ||||
| Assess | ||||||
| A fragment-based inhibitor of SHP2 | monomer | 4×FMT; 1×A1H4K; | ||||
| Assess | ||||||
| A fragment-based inhibitor of SHP2 | monomer | 1×FMT; 1×A1H4G; | ||||
| Assess | ||||||
| A fragment-based inhibitor of SHP2 | monomer | 1×A1H4S; | ||||
| Assess | ||||||
| A fragment-based inhibitor of SHP2 | monomer | 1×A1H4T; | ||||
| Assess | ||||||
| A fragment-based inhibitor of SHP2 | monomer | 1×A1H4R; | ||||
| Assess | ||||||
| A fragment-based inhibitor of SHP2 | monomer | 1×A1H4I; | ||||
| Assess | ||||||
| A fragment-based inhibitor of SHP2 | monomer | 1×A1H4L; | ||||
| Assess | ||||||
| A fragment-based inhibitor of SHP2 | monomer | 1×A1H4P; | ||||
| Assess | ||||||
| A fragment-based inhibitor of SHP2 | monomer | 1×A1H4O; | ||||
| Assess | ||||||
| A fragment-based inhibitor of SHP2 | monomer | 1×A1H4N; | ||||
| Assess | ||||||
| A fragment-based inhibitor of SHP2 | monomer | 1×A1H4J; | ||||
| Assess | ||||||
| A fragment-based inhibitor of SHP2 | monomer | 1×A1H4M; | ||||
| Assess | ||||||
| LEOPARD Syndrome-Associated SHP2/Q510E mutant | monomer | |||||
| Assess | ||||||
| The wild-type Src homology 2 (SH2)-domain containing protein tyrosine phosphatase-2 (SHP2) | monomer | |||||
| Assess | ||||||
| LEOPARD Syndrome-Associated SHP2/Y279C mutant | monomer | |||||
| Assess | ||||||
| Structure of human SHP2 in complex with inhibitor IACS-13909 | monomer | 1×U9Y; | ||||
| Assess | ||||||
| LEOPARD Syndrome-Associated SHP2/G464A mutant | monomer | |||||
| Assess | ||||||
| Closed structure of active SHP2 mutant E76K bound to SHP099 inhibitor | monomer | 1×5OD; | ||||
| Assess | ||||||
| LEOPARD Syndrome-Associated SHP2/Q506P mutant | monomer | |||||
| Assess | ||||||
| LEOPARD Syndrome-Associated SHP2/A461T mutant | monomer | |||||
| Assess | ||||||
| The atomic structure of SHP2 E76A mutant | monomer | |||||
| Assess | ||||||
| A fragment-based inhibitor of SHP2 | monomer | 1×A1H4Q; | ||||
| Assess | ||||||
| Cancer-associated SHP2/T507K mutant | monomer | |||||
| Assess | ||||||
| Crystal Structure of Shp2 E76K GOF Mutant in the Open Conformation | monomer | |||||
| Assess | ||||||
| Structure of human SHP2 in complex with compound 16 | monomer | 1×33I; | ||||
| Assess | ||||||
| Closed structure of inactive SHP2 mutant C459E | monomer | |||||
| Assess | ||||||
| Identification of GDC-1971 (RLY-1971), a SHP2 inhibitor designed for the treatment of solid tumors | monomer | 6×SO4; 1×YT2; | ||||
| Assess | ||||||
| A fragment-based inhibitor of SHP2 | monomer | 1×A1H4H; | ||||
| Assess | ||||||
| TYROSINE PHOSPHATASE SHP-2 | monomer | 1×CAT; | ||||
| Assess | ||||||
| Crystal structure of non-receptor protein tyrosine phosphatase SHP2 in complex with inhibitor compo… | monomer | 1×WAB; | ||||
| Assess | ||||||
| LEOPARD Syndrome-Associated SHP2/T468M mutant | monomer | |||||
| Assess | ||||||
| Identification of GDC-1971 (RLY-1971), a SHP2 inhibitor designed for the treatment of solid tumors | monomer | 5×SO4; 1×YR2; | ||||
| Assess | ||||||
| Oxidized SHP2 forms a disulfide bond between Cys367 and Cys459 | monomer | 1×PO4; | ||||
| Assess | ||||||
| Small-molecule Allosteric Regulation Mechanism of SHP2 | monomer | 1×KID; | ||||
| Assess | ||||||
| Structure of human SHP2 in complex with compound 30 | monomer | 1×3ED; | ||||
| Assess | ||||||
| Non-receptor Protein Tyrosine Phosphatase SHP2 in Complex with Allosteric Inhibitor RMC-4550 | monomer | 1×4Q4; 2×CL; | ||||
| Assess | ||||||
| SHP2 in complex with allosteric imidazopyrazine inhibitor | monomer | 1×P8O; 13×FMT; | ||||
| Assess | ||||||
| Non-receptor Protein Tyrosine Phosphatase SHP2 in Complex with Allosteric Inhibitor SHP836 | monomer | 1×5OA; 5×PO4; | ||||
| Assess | ||||||
| Structure of F285S, a Cancer-Associated Mutation of the Oncogenic Phosphatase SHP2 | monomer | |||||
| Assess | ||||||
| Non-receptor Protein Tyrosine Phosphatase SHP2 in Complex with Allosteric Inhibitor Pyrimidinone 7 | monomer | 1×JE1; 6×PO4; | ||||
| Assess | ||||||
| Non-receptor Protein Tyrosine Phosphatase SHP2 in Complex with Allosteric Inhibitor Imidazo-pyridin… | monomer | 1×JE7; 1×PO4; | ||||
| Assess | ||||||
| Non-receptor Protein Tyrosine Phosphatase SHP2 in Complex with Allosteric Inhibitor SHP504 | monomer | 1×DZS; 3×PO4; | ||||
| Assess | ||||||
| Non-receptor Protein Tyrosine Phosphatase SHP2 in Complex with Allosteric Inhibitors SHP099 and SHP… | monomer | 1×5OD; 1×DYV; 1×PO4; | ||||
| Assess | ||||||
| Identification of GDC-1971 (RLY-1971), a SHP2 inhibitor designed for the treatment of solid tumors | monomer | 1×ZH5; | ||||
| Assess | ||||||
| Non-receptor Protein Tyrosine Phosphatase SHP2 in Complex with Allosteric Inhibitor TK-453 | monomer | 1×83Q; | ||||
| Assess | ||||||
| Non-receptor Protein Tyrosine Phosphatase SHP2 in Complex with Allosteric Inhibitors SHP099 and SHP… | monomer | 1×5OD; 1×DZS; 2×PO4; | ||||
| Assess | ||||||
| Non-receptor Protein Tyrosine Phosphatase SHP2 in Complex with Allosteric Inhibitors SHP099 and SHP… | monomer | 1×5OD; 1×DZV; 1×PO4; 1×GOL; | ||||
| Assess | ||||||
| Non-receptor Protein Tyrosine Phosphatase SHP2 in Complex with Allosteric Inhibitor TNO155 | monomer | 1×VKS; 3×PO4; | ||||
| Assess | ||||||
| Non-receptor Protein Tyrosine Phosphatase SHP2 in Complex with Allosteric Inhibitor SHP244 | monomer | 1×DZV; 5×PO4; | ||||
| Assess | ||||||
| SHP2 in complex with a novel allosteric inhibitor | monomer | 1×U70; | ||||
| Assess | ||||||
| Identification of GDC-1971 (RLY-1971), a SHP2 inhibitor designed for the treatment of solid tumors | monomer | 1×ZJX; | ||||
| Assess | ||||||
| Non-receptor Protein Tyrosine Phosphatase SHP2 in Complex with Allosteric Inhibitor Pyrazolo-pyrimi… | monomer | 1×JE4; 2×PO4; | ||||
| Assess | ||||||
| Non-receptor Protein Tyrosine Phosphatase SHP2 in Complex with Allosteric Inhibitor SHP844 | monomer | 1×DYV; 3×PO4; | ||||
| Assess | ||||||
| Structure of human SHP2 in complex with compound 22 | monomer | 1×37I; | ||||
| Assess | ||||||
| Non-receptor Protein Tyrosine Phosphatase SHP2 in Complex with Allosteric Inhibitor SHP099 | monomer | 1×5OD; 3×PO4; | ||||
| Assess | ||||||
| Non-receptor Protein Tyrosine Phosphatase SHP2 in Complex with Allosteric Inhibitor Compound 24 | monomer | 1×VKP; 4×PO4; | ||||
| Assess | ||||||
| Crystal structure of non-receptor protein tyrosine phosphatase SHP2 in complex with inhibitor compo… | monomer | 1×W8I; | ||||
| Assess | ||||||
| NON-RECEPTOR PROTEIN TYROSINE PHOSPHATASE SHP2 IN COMPLEX WITH ALLOSTERIC INHIBITOR Isoxazolo-pyrid… | monomer | 1×JEJ; 1×PO4; | ||||
| Assess | ||||||
| Non-receptor Protein Tyrosine Phosphatase SHP2 in Complex with Allosteric Inhibitor Pyrazolo-pyrimi… | monomer | 1×JEA; 3×PO4; | ||||
| Assess | ||||||
| Structure of S502P, a Cancer-Associated Mutation of the Oncogenic Phosphatase SHP2 | monomer | |||||
| Assess | ||||||
| Non-receptor Protein Tyrosine Phosphatase SHP2 in Complex with Allosteric Inhibitor Pyrazolo-pyridi… | monomer | 1×JED; 1×PO4; | ||||
| Assess | ||||||
| Structure of E76Q, a Cancer-Associated Mutation of the Oncogenic Phosphatase SHP2 | monomer | |||||
| Assess | ||||||
| The Crystal Structure of SHP2 from Biortus. | monomer | 1×5OD; | ||||
| Assess | ||||||
| Crystal Structure of Shp2 E76K GOF Mutant in complex with SHP099 | monomer | 1×5OD; 4×SO4; 1×GOL; | ||||
| Assess | ||||||
| Structure of human SHP2 in complex with compound 27 | monomer | 1×3CW; | ||||
| Assess | ||||||
| Small-molecule Allosteric Regulation Mechanism of SHP2 | monomer | 1×FIZ; | ||||
| Assess | ||||||
| Non-receptor Protein Tyrosine Phosphatase SHP2 F285S in Complex with Allosteric Inhibitor JLR-2 | monomer | 1×DZJ; | ||||
| Assess | ||||||
| Structure of human SHP2 without N-SH2 domain | monomer | |||||
| Assess | ||||||
| Crystal structure of the human tyrosine phosphatase SHP2 (PTPN11) with an accessible active site | monomer | 1×MLT; | ||||
| Assess | ||||||
| Catalytic domain of human SHP2 | monomer | |||||
| Assess | ||||||
| Catalytic domain of human SHP2 | monomer | |||||
| Assess | ||||||
| Catalytic domain of human SHP2 | monomer | |||||
| Assess | ||||||
| Catalytic domain of human SHP2 | monomer | |||||
| Assess | ||||||
| Crystal structure of protein tyrosine phosphatase Shp2 catalytic domain complex with small molecula… | monomer | 1×2WT; | ||||
| Assess | ||||||
| Co-crystal structure of SHP2 in complex with a Cefsulodin derivative | monomer | 1×3LU; | ||||
| Assess | ||||||
| Crystal structure of the oncogenic tyrosine phosphatase SHP2 complexed with a salicylic acid-based … | monomer | 1×JZG; | ||||
| Assess | ||||||
| Crystal structure of SHP2 in complex with a tautomycetin analog TTN D-1 | monomer | 1×B2B; | ||||
| Assess | ||||||
| Structure of the SHP-2 N-SH2 domain in a 1:2 complex with RVIpYFVPLNR peptide | monomer | |||||
| Assess | ||||||
| Structure of SHP2 N-SH2 domain in complex with RLNpYAQLWHR peptide | monomer | 1×SO4; | ||||
| Assess | ||||||
1 SWISS-MODEL model
| Template | Oligo-state | QMEANDisCo | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|
| 4nwg.1.A | monomer | 0.87 | 99.81 | |||
| Assess | ||||||
2 SWISS-MODEL models built on isoform sequence
| Template | Isoform | Oligo-state | QMEANDisCo | Range | Ligands | Trg-Tpl Seq id (%) |
|---|---|---|---|---|---|---|
| Isoform 1 | 4nwg.1.A | monomer | 0.85 | 99.81 | ||
| Assess | ||||||
| Isoform 3 | 5ehp.1.A | monomer | 0.85 | 99.78 | ||
| Assess | ||||||